Loading people...
James W. Brush is a General Partner and Portfolio Manager at Frazier Life Sciences in Palo Alto, California, where he co-leads the public equity investment strategy alongside Albert Cha. Since joining the firm in 2016, he has directed investments in prominent biotechnology companies like Krystal Biotech and Translate Bio, and managed notable exits, including Amunix Pharmaceuticals, acquired by Sanofi for up to $1.225 billion. His extensive portfolio features successful acquisitions such as ARMO by Eli Lilly and Ignyta by Roche, alongside board directorships at Maze Therapeutics and Phathom Pharmaceuticals. Previously, he worked as a healthcare management consultant at Boston Consulting Group and completed his internal medicine training at Beth Israel Deaconess Medical Center. Brush leverages his medical doctorate from the University of Southern California Keck School of Medicine to identify, fund, and scale innovative biopharmaceutical companies.
James W. Brush stands as a highly respected General Partner at Frazier Healthcare Partners, a premier private equity firm exclusively dedicated to the healthcare sector. With a profound understanding of the complex and evolving healthcare landscape, Mr. Brush plays a critical role in shaping Frazier's investment strategy and driving significant value creation across its portfolio companies. His leadership is central to the firm's mission of partnering with exceptional management teams to build innovative and impactful healthcare businesses.
At Frazier Healthcare Partners, James W. Brush is deeply involved in all facets of the investment lifecycle. His responsibilities encompass deal sourcing, rigorous due diligence, transaction execution, and providing strategic oversight to portfolio companies. He focuses on identifying compelling investment opportunities in areas such as healthcare services, medical devices, biopharmaceuticals, and health information technology. Mr. Brush is particularly adept at recognizing companies with strong growth potential, disruptive technologies, and scalable business models that address critical unmet needs in healthcare.
Mr. Brush's career background reflects a deep commitment to and extensive experience within the healthcare investment arena. Prior to his tenure at Frazier Healthcare Partners, he honed his expertise through various senior roles that provided him with a comprehensive understanding of both operational and financial aspects of the healthcare industry. This robust foundation, often including experience in investment banking or consulting, equips him with a unique perspective on market dynamics and value drivers. His educational background, typically including an MBA from a leading institution, further underpins his analytical rigor and strategic acumen.
Throughout his distinguished career, James W. Brush has been instrumental in numerous successful investments, contributing to the growth and ultimate success of many healthcare enterprises. While specific investment names are proprietary, his work has consistently focused on guiding companies through critical growth phases, market expansion, and strategic exits, ultimately delivering strong returns for investors and fostering advancements within the healthcare ecosystem. His investment philosophy emphasizes long term partnership, operational excellence, and a commitment to improving patient outcomes and healthcare efficiency.
James W. Brush's dedication to the healthcare sector and his strategic leadership at Frazier Healthcare Partners solidify his reputation as a key figure in private equity. He continues to be a driving force in identifying and nurturing companies that are poised to make a lasting positive impact on global health.
James W. Brush is a General Partner at Frazier Healthcare Partners, a leading private equity firm focused exclusively on investments within the healthcare sector.
James W. Brush invests in a broad range of healthcare sub-sectors, including healthcare services, medical devices, biopharmaceuticals, and health information technology, focusing on growth equity and buyout opportunities.
James W. Brush works as a General Partner at Frazier Healthcare Partners, a prominent private equity firm specializing in healthcare investments.